Notice of Dividend

RNS Number : 4964P
The MedicX Fund Limited
08 February 2019
 

 

 

Press Release

For immediate release 

8 February 2019

 

MedicX Fund Limited

("MedicX", the "Fund" or the "Company")

 

Notice of Dividend

 

The Directors have approved a quarterly dividend of 0.95p per Ordinary Share in respect of the period 1 October 2018 to 31 December 2018 (the "March 2019 Dividend"). The dividend will be paid on the earlier of (i) 29 March 2019; and (ii) the Effective Date of the recommended all-share merger between the Company and Primary Health Properties PLC as announced on 24 January 2019 (the "Merger"), to ordinary shareholders on the register as at 15 February 2019 (the "Record Date"). The corresponding ex-dividend date will be 14 February 2019.

 

This quarterly dividend will comprise 65% (0.6175p) Property Income Distribution ("PID") and 35% ordinary dividend (0.3325p). For shareholders who qualify for gross payment of distributions, forms to register for gross PIDs are available on the Company's website at http://www.medicxfund.com/investors/declaration-eligibility-pid-paymentsEligibility declarations must be returned to the Company's registrar, Link Asset Services, Corporate Actions, The Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU to arrive by the Record Date. Please click on the above link or refer to the Company's website to obtain an eligibility declaration form.

 

As a result of the Merger, the Company is not offering qualifying shareholders the opportunity to take new ordinary shares in the Company, credited as fully paid, in lieu of the net cash dividend in respect if the March 2019 Dividend.

 

 

End

For further information please contact:

Octopus Healthcare Adviser Ltd

+44 (0) 345 0404 5555

 

Octopus Healthcare

 +44 (0) 20 3142 4820

Mike Adams, Executive Chairman

 

Maitland/AMO

+44 (0) 20 7379 5151

Andy Donald/Jason Ochere

 

 

 

Information on MedicX Fund Limited

 

MedicX Fund Limited ("MXF", "MedicX Fund", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom and Ireland, listed on the London Stock Exchange, with a portfolio comprising 165 properties.

 

The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is part of the Octopus Healthcare group. Octopus Healthcare invests in and develops properties as well as creating partnerships to deliver innovative healthcare buildings to improve the health, wealth and wellbeing of the UK. It currently manages over £1.5 billion of healthcare investments across a number of platforms, with a focus on three core areas: GP surgeries, care homes and retirement housing. Octopus Healthcare is part of the Octopus group, a fast-growing UK fund management business with leading positions in several specialist sectors including healthcare property, energy, property finance and smaller company investing. Octopus manages £8.6 billion of funds for more than 65,000 retail and institutional investors as well as supplying energy to more than 450,000 customers.

 

Octopus Healthcare Adviser Ltd is authorised and regulated by the Financial Conduct Authority.

 

The Company's website address is www.medicxfund.com. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website), nor the contents of any website accessible from hyperlinks within this announcement, are incorporated into, or forms part of, this announcement.

 

The Company's Legal Entity Identifier is 2138008POF35FTNFCB25.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUGUUCPUPBUBR
UK 100

Latest directors dealings